APA (7th ed.) Citation

Kim, E., Park, S., Cho, D. S., Youn, J., Lee, H. S., Lee, H., . . . Baek, S. H. (2024). Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea. American Journal of Cardiovascular Drugs, 24(2), 313-324. https://doi.org/10.1007/s40256-024-00632-w

Chicago Style (17th ed.) Citation

Kim, Eui-Soon, et al. "Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea." American Journal of Cardiovascular Drugs 24, no. 2 (2024): 313-324. https://doi.org/10.1007/s40256-024-00632-w.

MLA (9th ed.) Citation

Kim, Eui-Soon, et al. "Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea." American Journal of Cardiovascular Drugs, vol. 24, no. 2, 2024, pp. 313-324, https://doi.org/10.1007/s40256-024-00632-w.